ClinicalTrials.gov Search Results 04/07/2020

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 1 | [Study of Obatoclax in Previously Untreated Acute Myeloid](https://ClinicalTrials.gov/show/NCT00684918) [Leukemia (AML)](https://ClinicalTrials.gov/show/NCT00684918) | Completed | No Results Available | * AML | * Drug: Obatoclax | * Northwestern University, Chicago, Illinois, United States * The University of Iowa, Iowa City, Iowa, United States * University of Kansas Medical Center Research Institute, Westwood, Kansas, United States * Dana Farber Cancer Institute, Boston, Massachusetts, United States * St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States * University of Michigan Health System, Ann Arbor, Michigan, United States * Michigan State University - Breslin Cancer Center, Lansing, Michigan, United States * St. Vincent's Comprehensive Cancer Center, New York, New York, United States * Legacy Emanuel Hospital & Health Center, Portland, Oregon, United States * Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey, Pennsylvania, United States * and 3 more |
| 2 | [A Phase I/II Study of GX15-070MS in Untreated CLL](https://ClinicalTrials.gov/show/NCT00600964) | Completed | No Results Available | * Chronic Lymphocytic Leukemia | * Drug: GX15-070MS | * University of CA- San Diego, La Jolla, California, United States * Lombardi Cancer Center, Washington, District of Columbia, United States * Milton S Hershey Medical Center Penn State Cancer Institute, Hershey, Pennsylvania, United States * UT MD Anderson Cancer Center, Houston, Texas, United States * Princess Margaret Hospital, Toronto, Ontario, Canada |
| 3 | [A Phase I/II Study of Carboplatin and Etoposide With or](https://ClinicalTrials.gov/show/NCT00682981) [Without Obatoclax in Extensive-stage Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00682981) [(ES-SCLC)](https://ClinicalTrials.gov/show/NCT00682981) | Completed | No Results Available | * Extensive-stage Small Cell Lung Cancer | * Drug: Obatoclax * Drug: Carboplatin/etoposide | * Clearview Cancer Institute, Huntsville, Alabama, United States * Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States * Mayo Clinic-Arizona, Scottsdale, Arizona, United States * Arizona Clinical Research Center, Tucson, Arizona, United States * City of Hope and Beckman Research Institute, Duarte, California, United States * University of California-San Diego Moores Cancer Center, LaJolla, California, United States * Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States * Integrated Community Oncology Network, Jacksonville, Florida, United States * University of Miami-Sylvester Cancer Center, Miami, Florida, United States * Florida Cancer Institute, New Port Richey, Florida, United States * and 65 more |
| 4 | [Safety and Efficacy of Single Agent Obatoclax Mesylate](https://ClinicalTrials.gov/show/NCT00427856) [(GX15-070MS) Followed by a Combination With Rituximab for](https://ClinicalTrials.gov/show/NCT00427856) [Previously-untreated Follicular Lymphoma (FL)](https://ClinicalTrials.gov/show/NCT00427856) | Completed | No Results Available | * Lymphoma, Follicular | * Drug: Obatoclax mesylate * Drug: Rituximab | * The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 5 | [Obatoclax and Bortezomib in Treating Patients With](https://ClinicalTrials.gov/show/NCT00538187) [Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma](https://ClinicalTrials.gov/show/NCT00538187) | Terminated | No Results Available | * Adult Non-Hodgkin Lymphoma * Recurrent Adult Diffuse Large Cell Lymphoma * Recurrent Grade 1 Follicular Lymphoma * Recurrent Grade 2 Follicular Lymphoma * Recurrent Grade 3 Follicular Lymphoma * Recurrent Mantle Cell Lymphoma * Recurrent Marginal Zone Lymphoma * Recurrent Small Lymphocytic Lymphoma | * Drug: obatoclax mesylate * Drug: bortezomib * Other: laboratory biomarker analysis * Other: pharmacological study | * City of Hope Medical Center, Duarte, California, United States |
| 6 | [Obatoclax for Systemic Mastocytosis](https://ClinicalTrials.gov/show/NCT00918931) | Terminated | Has Results | * Leukemia * Systemic Mastocytosis | * Drug: Obatoclax Mesylate | * UT MD Anderson Cancer Center, Houston, Texas, United States |
| 7 | [Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in](https://ClinicalTrials.gov/show/NCT00359892) [the Treatment of Hodgkin's Lymphoma](https://ClinicalTrials.gov/show/NCT00359892) | Completed | No Results Available | * Hodgkin's Lymphoma | * Drug: Obatoclax mesylate (GX15-070MS) | * MD Anderson Cancer Center, Houston, Texas, United States |
| 8 | [Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in](https://ClinicalTrials.gov/show/NCT00407303) [Combination With Bortezomib for the Treatment of Relapsed](https://ClinicalTrials.gov/show/NCT00407303) [or Refractory Mantle Cell Lymphoma (MCL)](https://ClinicalTrials.gov/show/NCT00407303) | Completed | No Results Available | * Mantle-Cell Lymphoma | * Drug: Obatoclax mesylate * Drug: Bortezomib | * NW Georgia Oncology Centers, Marietta, Georgia, United States * Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States * Hackensack University Medical Center, Hackensack, New Jersey, United States * Roswell Park Medical Center, Buffalo, New York, United States * University of Wisconsin, Madison, Wisconsin, United States |
| 9 | [Obatoclax, Fludarabine, and Rituximab in Treating Patients](https://ClinicalTrials.gov/show/NCT00612612) [With Previously Treated Chronic Lymphocytic Leukemia](https://ClinicalTrials.gov/show/NCT00612612) | Terminated | No Results Available | * B-cell Chronic Lymphocytic Leukemia * Leukemia * Prolymphocytic Leukemia * Refractory Chronic Lymphocytic Leukemia * Stage I Chronic Lymphocytic Leukemia * Stage II Chronic Lymphocytic Leukemia * Stage III Chronic Lymphocytic Leukemia * Stage IV Chronic Lymphocytic Leukemia | * Drug: obatoclax mesylate * Drug: fludarabine phosphate * Biological: rituximab * Other: laboratory biomarker analysis | * Dana-Farber Cancer Institute, Boston, Massachusetts, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 10 | [Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for](https://ClinicalTrials.gov/show/NCT00413114) [the Treatment of Myelodysplastic Syndromes (MDS)](https://ClinicalTrials.gov/show/NCT00413114) | Completed | No Results Available | * Myelodysplastic Syndromes | * Drug: Obatoclax mesylate (GX15-070MS) | * Stanford University, Stanford, California, United States * Georgetown University Medical Center, Washington, District of Columbia, United States * James A. Haley Veterans Hospital, Tampa, Florida, United States * Emory University School of Medicine/ Winship Cancer Center, Atlanta, Georgia, United States * Northwest Georgia Oncology Centers, Marietta, Georgia, United States * University of Chicago, Chicago, Illinois, United States * University of Massachusetts Medical Center, Worcester, Massachusetts, United States * Michigan State University, Breslin Cancer Center CTO, Lansing, Michigan, United States * Hematology-Oncology Centers of the Northern Rockies, Billings, Montana, United States * St. Vincent's Comprehensive Cancer Center, New York, New York, United States * and 12 more |
| 11 | [Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in](https://ClinicalTrials.gov/show/NCT00405951) [Combination With Docetaxel for the Treatment of Non-Small](https://ClinicalTrials.gov/show/NCT00405951) [Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00405951) | Completed | No Results Available | * Lung Cancer | * Drug: Obatoclax mesylate 250 ml * Drug: Docetaxel | * Mayo Clinic College of Medicine, Scottsdale, Arizona, United States * Tower Oncology, Beverly Hills, California, United States * Georgetown University, Washington, District of Columbia, United States * H. Lee Moffitt Cancer Center, Tampa, Florida, United States * University of Maryland, Baltimore, Maryland, United States * MedStar Research Institute, Baltimore, Maryland, United States * Arlington Cancer Center, Arlington, Texas, United States |
| 12 | [Efficacy and Safety of Obatoclax Mesylate in Combination](https://ClinicalTrials.gov/show/NCT01563601) [With Carboplatin and Etoposide Compared With Carboplatin](https://ClinicalTrials.gov/show/NCT01563601) [and Etoposide Alone in Chemotherapy-Naive Patients With](https://ClinicalTrials.gov/show/NCT01563601) [Extensive-Stage Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT01563601) | Withdrawn | No Results Available | * Extensive-stage Small Cell Lung Cancer | * Drug: Obatoclax Mesylate, Carboplatine and Etoposide * Drug: Carboplatin and Etoposide |  |
| 13 | [Obatoclax and Bortezomib in Treating Patients With Relapsed](https://ClinicalTrials.gov/show/NCT00719901) [or Refractory Multiple Myeloma](https://ClinicalTrials.gov/show/NCT00719901) | Terminated | Has Results | * Refractory Multiple Myeloma * Stage I Multiple Myeloma * Stage II Multiple Myeloma * Stage III Multiple Myeloma | * Drug: obatoclax mesylate * Drug: bortezomib * Other: laboratory biomarker analysis | * Mayo Clinic, Rochester, Minnesota, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 14 | [Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin](https://ClinicalTrials.gov/show/NCT00933985) [Hydrochloride, and Dexrazoxane Hydrochloride in Treating](https://ClinicalTrials.gov/show/NCT00933985) [Young Patients With Relapsed or Refractory Solid Tumors,](https://ClinicalTrials.gov/show/NCT00933985) [Lymphoma, or Leukemia](https://ClinicalTrials.gov/show/NCT00933985) | Terminated | No Results Available | * Acute Leukemias of Ambiguous Lineage * Acute Undifferentiated Leukemia * Angioimmunoblastic T-cell Lymphoma * Blastic Phase Chronic Myelogenous Leukemia * Childhood Burkitt Lymphoma * Childhood Chronic Myelogenous Leukemia * Childhood Diffuse Large Cell Lymphoma * Childhood Immunoblastic Large Cell Lymphoma * Childhood Nasal Type Extranodal NK/T-cell Lymphoma * Cutaneous B-cell Non-Hodgkin Lymphoma * and 19 more | * Drug: dexrazoxane hydrochloride * Drug: doxorubicin hydrochloride * Drug: obatoclax mesylate * Drug: liposomal vincristine sulfate * Other: pharmacological study * Other: laboratory biomarker analysis | * University of Alabama at Birmingham, Birmingham, Alabama, United States * Childrens Hospital of Orange County, Orange, California, United States * Children's National Medical Center, Washington, District of Columbia, United States * Lurie Children's Hospital-Chicago, Chicago, Illinois, United States * Indiana University Medical Center, Indianapolis, Indiana, United States * Dana-Farber Cancer Institute, Boston, Massachusetts, United States * C S Mott Children's Hospital, Ann Arbor, Michigan, United States * University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States * Washington University School of Medicine, Saint Louis, Missouri, United States * Columbia University Medical Center, New York, New York, United States * and 10 more |
| 15 | [Obatoclax Mesylate and Topotecan Hydrochloride in Treating](https://ClinicalTrials.gov/show/NCT00521144) [Patients With Relapsed or Refractory Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00521144) [or Advanced Solid Tumors](https://ClinicalTrials.gov/show/NCT00521144) | Completed | Has Results | * Recurrent Small Cell Lung Cancer * Unspecified Adult Solid Tumor, Protocol Specific | * Drug: obatoclax mesylate * Drug: topotecan hydrochloride * Other: laboratory biomarker analysis | * Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States * Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| 16 | [Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in](https://ClinicalTrials.gov/show/NCT00360035) [the Treatment of Myelofibrosis With Myeloid Metaplasia](https://ClinicalTrials.gov/show/NCT00360035) | Completed | No Results Available | * Myelofibrosis | * Drug: Obatoclax mesylate (GX15-070MS) | * Georgetown University Medical Center, Washington, District of Columbia, United States * James A. Haley Veterans Hospital, Tampa, Florida, United States * Emory University, Atlanta, Georgia, United States * The University of Chicago, Chicago, Illinois, United States * University of Massachusetts Medical Center, Worcester, Massachusetts, United States * MD Anderson Cancer Center, Houston, Texas, United States * Princess Margaret Hospital, Toronto, Ontario, Canada |
| 17 | [Obatoclax Mesylate, Rituximab, and Bendamustine](https://ClinicalTrials.gov/show/NCT01238146) [Hydrochloride in Treating Patients With Relapsed or](https://ClinicalTrials.gov/show/NCT01238146) [Refractory Non-Hodgkin Lymphoma](https://ClinicalTrials.gov/show/NCT01238146) | Withdrawn | No Results Available | * Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue * Nodal Marginal Zone B-cell Lymphoma * Recurrent Grade 1 Follicular Lymphoma * Recurrent Grade 2 Follicular Lymphoma * Recurrent Mantle Cell Lymphoma * Recurrent Marginal Zone Lymphoma * Splenic Marginal Zone Lymphoma | * Drug: bendamustine hydrochloride * Drug: obatoclax mesylate * Biological: rituximab | * Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States |
| 18 | [Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for](https://ClinicalTrials.gov/show/NCT00438178) [the Treatment of Hematological Malignancies](https://ClinicalTrials.gov/show/NCT00438178) | Completed | No Results Available | * Hematological Malignancies | * Drug: Obatoclax mesylate (GX15-070MS) | * Georgetown University Medical Center, Washington, District of Columbia, United States * MD Anderson Cancer Center, Houston, Texas, United States * Princess Margaret Hospital, Toronto, Ontario, Canada |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 19 | [A Phase I/II Study of GMX1777 in Combination With](https://ClinicalTrials.gov/show/NCT00724841) [Temozolomide for the Treatment of Metastatic Melanoma](https://ClinicalTrials.gov/show/NCT00724841) | Terminated | No Results Available | * Metastatic Melanoma | * Drug: Obatoclax Mesylate * Drug: Temozolomide | * University of Pennsylvania, Philadelphia, Pennsylvania, United States |
| 20 | [Obatoclax Mesylate in Samples From Young Patients With](https://ClinicalTrials.gov/show/NCT01150656) [Acute Myeloid Leukemia](https://ClinicalTrials.gov/show/NCT01150656) | Completed | No Results Available | * Leukemia | * Genetic: gene expression analysis * Genetic: microarray analysis * Genetic: protein expression analysis * Genetic: reverse transcriptase-polymerase chain reaction * Genetic: western blotting * Other: laboratory biomarker analysis * Other: pharmacological study |  |

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services